in partnering talks for Alzheimer drug
Send a link to a friend
[May 07, 2014]
fighting a $106 billion bid approach from Pfizer, is talking to
other companies as it seeks a partnering deal for its experimental
Briggs Morrison, global head of medicines
development, said AstraZeneca was talking to companies with more
experience of Alzheimer's about a deal to share development of its
so-called BACE inhibitor drug, which is set to enter late-stage
Phase III development.
A deal to share Phase III costs and share eventual profits was
probably the easiest approach, he told reporters on Wednesday, but
AstraZeneca could also out-license the product and take a royalty on
any eventual sales.
AstraZeneca believes its BACE inhibitor could potentially sell as
much as $5 billion a year, but it gives it only a 9 percent chance
of success on a risk adjusted basis given the high failure rate in
the disease sector.
The British company on Tuesday set out its defence against the
Pfizer takeover, touting its strong long-term growth potential as an
(Reporting by Ben Hirschler, editing by Kate Holton)
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.